Kubota Pharmaceutical Holdings Co., Ltd.
Basic information
- Head office
- 15-37, 1-chome Minami-Aoyama, Minato-ku, Tokyo 107-0062, Japan
- Chief executive
- Dr. Ryo Kubota, MD, PhD
- Capital
- 33,000,000 JPY
- Employees (non-consolidated)
- 8 people
- Employees (consolidated)
- Start date
- 2015-12-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
Network
History
Established Acugen Neuropeutics Inc. in Seattle, Washington, USA, to develop treatments for degenerative eye diseases and screening systems for pharmaceuticals.![]()
Relocated all departments, including headquarters and research facilities, to Bellingham, Washington, USA.![]()
Commenced development of the visual cycle modulator 'Emixstat Sodium Salt' for retinal disease treatment.![]()
Submitted IND for 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration to the FDA.![]()
Initiated Phase 1 clinical trial of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration.![]()
Entered joint development and joint sales agreement with Otsuka Pharmaceutical Co., Ltd. for our key compound 'Emixstat Sodium Salt'.![]()
FDA designated 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration as Fast Track.![]()
Relocated headquarters, including administration and clinical development divisions, to Seattle, Washington.![]()
Initiated Phase 2b/3 clinical trials of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration.![]()
Announced results of Phase 2a clinical trial of 'Emixstat Sodium Salt' for geographic atrophy-associated dry age-related macular degeneration.![]()
Established subsidiary Acucela Japan Co., Ltd. (now Kubota Pharmaceutical Holdings Co., Ltd.) in Shibuya-ku, Tokyo.![]()
Signed exclusive agreement with the University of Manchester for development and commercialization of gene therapy technology for retinal degenerative diseases.![]()
Initiated Phase II clinical trial of 'Emixstat Hydrochloride' for proliferative diabetic retinopathy.![]()
Announced results of Phase 2b/3 clinical trial of 'Emixstat Hydrochloride' for dry age-related macular degeneration with geographic atrophy.![]()
Ended joint development and joint sales agreement for 'Emixstat Hydrochloride' with Otsuka Pharmaceutical Co., Ltd.![]()
Implemented headquarter relocation to Japan via triangular merger, and Kubota Pharmaceutical Holdings Inc. made AcuSera Inc. a wholly-owned subsidiary.![]()
Entered into an option agreement with EyeMedics Inc. for exclusive rights to worldwide manufacturing, development, and sales of a new biomimetic technology.![]()
Signed joint development agreement with SIRION Biotech GmbH for gene delivery technology aimed at ophthalmic gene therapy research.![]()
Announced results of Phase II clinical trial of 'Emixstat Hydrochloride' for proliferative diabetic retinopathy.![]()
Signed contract to develop a small OCT (optical coherence tomography) device for NASA's deep space missions.![]()
FDA selected Phase III clinical trial of 'Emixstat Hydrochloride' for Stargardt disease for the Orphan Products Clinical Trials Grants Program.![]()
The wearable myopia device 'Kubota Glasses', aimed at suppressing and treating myopia progression, successfully completed a proof-of-concept (POC) test using wearable devices.![]()
News
There is no news.
Public records
National Tax Agency basic information3011001108646
- Trade name
- 窪田製薬ホールディングス株式会社
- Trade name (kana)
- クボタセイヤクホールディングス
- Name in English
- Corporation type
- 301
- Address
- 〒107-0062 東京都港区南青山1丁目15番37号
- Postal code
- 1070062
- Prefecture code
- 13
- City code
- 103
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-12-17
- Update date
- 2023-06-21
- Change date
- 2023-06-16
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 0
- Trade name image ID
- Address image ID
- Sequence number
- 1642593
METI gBizINFO3011001108646
- Corporate number
- 3011001108646
- Trade name
- 窪田製薬ホールディングス株式会社
- Trade name (kana)
- クボタセイヤクホールディングス
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都港区南青山1丁目15番37号
- Postal code
- 1070062
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 港区
- City code
- 103
- Street address
- 南青山1丁目15番37号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 0
- Status
- Representative
- 代表取締役会長、社長兼最高経営責任者 窪田 良
- Capital
- 577576000
- Employees
- 7
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-06-21
- Key information
- 3011001108646